Previous Next


№3' 2017


International Medical Journal, Vol. 23., Iss. 3, 2017, P. 54−58.


Mikhanovskyi A. A., Yakovtsova I. I., Yuliia Vladimirovna Kharchenko, Olga Vladimirovna Slobodianiuk, Shchyt N. M., Fedorenko N. V.

S. P. Grigoriev Institute for Medical Radiology (NAMS of Ukraine), Ukraine

Development of new methods of treatment of patients with ovarian cancer based on the achievements of fundamental science is an urgent issue. According to the researchers, treatment with neoadjuvant chemotherapy at the first stage can improve the tumor resectability, increase the frequency of optimal cytoreductive operations in patients with advanced ovarian cancer. The prognosis of the disease depends not only on its stage and the strategy of antitumor treatment, but also a number of factors, including molecular ones, that determine the biological properties of ovarian cancer. To determine the group of increased risk of relapses and metastases in patients with stage III−IV ovarian cancer, immunohistological examination of the levels of expression of molecular−biological markers in the tumor after neoadjuvant chemotherapy was performed. Depending on the type of combination treatment, the patients were divided into two groups: group 1 was performed surgical treatment followed by adjuvant chemotherapy. In group 2 the treatment was started with neoadjuvant chemotherapy (1ЃE cycles) followed by surgical treatment and adjuvant chemotherapy. Investigation of molecular−biological markers in tumors of patients with stage III−IV ovarian cancer has prognostic value for determination of high−risk groups depending on the type of relapse (genitalization of the process in the abdominal cavity with certain metastases, locoregional and marker relapses), which allows individualizing antitumor therapy modes. Relationship between the level of molecular−biological markers expression in the tumor of patients and the type of ovarian cancer recurrence. Thus, at generalization of the process, expression of VEGF and Bcl−2 is absent and high expression of mt p53 and Kі−67 is observed. On the contrary, in patients with locoregional and marker relapses, high expression of Bcl−2 protein and mt p53 occurs, but the parameters of proliferative activity and the growth factor of the vascular endothelium differ. The obtained data allow to determine molecular−biological markers most important for disease prediction in patients with ovarian cancer and to correct treatment methods.

Key words: ovarian cancer, molecular−biological markers, relapse, combination treatment.

Go on Top